Clinical severity and patterns of organ involvement in acute systemic lupus erythematosus flares and predictors of disease severity: a retrospective study
DOI:
https://doi.org/10.18203/2320-6012.ijrms20252413Keywords:
SLE, SLEDAI, Disease activity, Thrombocytopenia, Red blood cell distribution width, Mean platelet volume, Prognosis , Mortality, Neuropsychiatric lupusAbstract
Background: Acute, severe flares of systemic lupus erythematosus (SLE) are associated with significant morbidity and mortality, yet robust, accessible predictors for poor outcomes are not fully established. We aimed to identify the clinical and laboratory characteristics associated with in-hospital mortality in patients with severe SLE flares.
Methods: We conducted a retrospective, cross-sectional study of 30 adult patients admitted for a severe SLE flare (SLE disease activity index 2000 [SLEDAI-2K] score >6) to a tertiary care center in Bhubaneswar, India, between January 2024 and January 2025. We extracted demographic, clinical, and comprehensive laboratory data. Pearson’s correlation was used to assess the relationship between SLEDAI-2K and laboratory parameters. Baseline characteristics were compared between survivors and non-survivors to identify predictors of the primary outcome, in-hospital mortality.
Results: The cohort was predominantly female (80.0%) with a median age of 28 years and high disease activity at admission (median SLEDAI-2K, 17.5). The overall in-hospital mortality rate was 13.3% (4 of 30). Disease activity strongly correlated with red cell distribution width (r=0.892), anti-dsDNA levels (r=0.760), complement C3 (r=–0.846), and mean platelet volume (r=–0.820; all p<0.001). Compared to survivors, non-survivors had significantly higher median SLEDAI-2K scores (29.0 versus 16.0, p<0.001) and a higher frequency of neurological involvement (75.0% versus 15.4%, p=0.025). Severe leukopenia (median WBC 1.8 versus 7.2×103/μl, p<0.001) and thrombocytopenia (median platelets 42.5 versus 172.0×103/μl, p=0.005) were also significantly associated with mortality.
Conclusions: In patients hospitalized for severe SLE flares, high baseline disease activity, neurological involvement, and profound cytopenias are key predictors of in-hospital mortality. Readily available hematological indices, particularly RDW and MPV, correlate strongly with disease activity and may serve as useful adjuncts for risk stratification.
Metrics
References
Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-21. DOI: https://doi.org/10.1056/NEJMra1100359
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum. 1997;40(9):1725. DOI: https://doi.org/10.1002/art.1780400928
Tektonidou MG, Dasgupta A, Ward MM. Risk of hospitalization for serious infections in patients with systemic lupus erythematosus: a population-based study. Arthritis Care Res (Hoboken). 2016;68(7):930-6.
Bertsias GK, Tektonidou M, Amoura Z, Flöel A, Boumpas DT, Jayne D, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-82. DOI: https://doi.org/10.1136/annrheumdis-2012-201940
Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002;16(5):847-58. DOI: https://doi.org/10.1053/berh.2002.0259
Ainiala H, Hietaharju A, Loukkola J, Peltola J. The diverse clinical manifestations of neuro-psychiatric systemic lupus erythematosus. J Neurol. 2007;254(9):1227-33.
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Autoimmun Rev. 2010;9(4):271-8. DOI: https://doi.org/10.1136/ard.2008.101766
Frieri M, Stampfl H. Systemic lupus erythematosus and the role of autoantibodies in its pathogenesis. Curr Allergy Asthma Rep. 2003;3(5):395-402.
Fayyaz A, Igoe A, Kurien BT, Danda D, James JA, Stafford HA, et al. Haematological manifestations of lupus. Lupus Sci Med. 2015;2(1):e000078. DOI: https://doi.org/10.1136/lupus-2014-000078
Scharte M, Fink MP. Red blood cell physiology in critical illness. Crit Care Med. 2003;31(12 Suppl):S651-7. DOI: https://doi.org/10.1097/01.CCM.0000098036.90796.ED
Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1):47-58. DOI: https://doi.org/10.2174/138161211795049804
Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017;56(11):1945-61. DOI: https://doi.org/10.1093/rheumatology/kex260
Maroz N, Mossey PA. The evidence for the use of corticosteroids in the management of lupus nephritis. J Am Soc Nephrol. 2006;17(4 Suppl 2):S123-7.
Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G, Guidi GC. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med. 2009;133(4):628-32. DOI: https://doi.org/10.5858/133.4.628
Vizioli J, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63(10):1509-15. DOI: https://doi.org/10.1111/j.1742-1241.2009.02070.x
Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al. Prospective analysis of neuropsychiatric events in a national cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69(3):529-35. DOI: https://doi.org/10.1136/ard.2008.106351
Yazici Y, Biyikli M, Erkan D, Akman-Demir G, Ozbek S, Yurdakul S, et al. The systemic lupus erythematosus disease activity index 2000 is valid and practical for routine use in busy clinical settings. Ann Rheum Dis. 2003;62(5):483-4.
Downloads
Published
How to Cite
Issue
Section
